5月份，增量政策可能不多，但储备政策不少，政策定力仍然很强，目标是应对关税的冲击。因此，市 场在度过业绩风险后仍然会关注科技成长主题。内需相关板块仍会是国内政策的首要着力点，低利率环 境下业绩稳定的高股息板块仍有配置价值。除此以外，在可能出现的关税缓和过程中，那些品牌力强、 定价能力强、替代难度大的公司有望迎来估值的修复。 谭小兵：看好有边际变化的成长股 4月份市场呈现V字形走势，内需与红利好于成长股。展望5月份，进入业绩真空期，市场对指数填补之 后能否继续上攻还是存在分歧，个人相对还是偏乐观：一方面是国内政策会逐步兑现；另一方面中美谈 判或拉开序幕，这有利于修复市场的风险偏好。方向上看好有边际变化的成长股。 回顾4月，美国"对等关税"来袭，全球市场剧烈波动，就中国资产来看，月内A股和港股主要指数收 跌。进入5月，尽管外部不确定性因素依然存在，但中美关税谈判窗口有望来临，国内一揽子增量政策 也在加速落地，为国内股市稳定发展带来有力支撑。 展望后市，市场将会如何演绎？哪些投资机会值得关注？一起来看看长城基金权益基金经理们的观点吧 ~ 杨建华：持续关注关税政策 展望5月，关税政策及中美贸易谈判仍将会成为左右市场的 ...

Group 1 - The core viewpoint is that the pharmaceutical sector is focusing on innovation, with a positive trend in innovative drugs supported by policies and increasing global competitiveness [2] - The Shanghai Stock Exchange Science and Technology Innovation Board Biomedicine Index has shown a 1.27% increase, indicating a recovery in the biotech sector [1] - The ETF tracking the Biomedicine Index has seen a 1.17% rise, with significant trading volume exceeding 8.12 million yuan, reflecting investor interest [1] Group 2 - The pharmaceutical industry is expected to see a recovery in demand by 2025, particularly in the consumer healthcare sector, driven by improving economic fundamentals [2] - The medical device sector is also anticipated to improve by 2025, indicating a broader recovery in the healthcare industry [2] - AI in healthcare is highlighted as a significant technological trend that could bring changes to the pharmaceutical industry [2] Group 3 - The pharmaceutical index has stabilized after a period of decline since 2021, with signs of recovery beginning in Q4 2024 [2] - The ongoing innovation in the pharmaceutical sector, along with favorable drug procurement policies, is expected to drive a new growth cycle [2] - The aging population and unmet clinical needs are contributing to long-term growth trends in the pharmaceutical industry [2]

截至2025年5月13日 09:39，恒生医疗保健指数(HSHCI)强势上涨1.38%，成分股百济神州(06160)上涨5.16%，医脉通(02192)上涨5.15%，乐普生物-B(02157)上 涨4.67%，信达生物(01801)，翰森制药(03692)等个股跟涨。恒生医疗ETF(513060)上涨1.72%，最新价报0.47元。流动性方面，恒生医疗ETF盘中换手 3.08%，成交3.05亿元。拉长时间看，截至5月12日，恒生医疗ETF近1月日均成交13.50亿元，排名可比基金第一。 德邦证券指出，AI的发展带动AI医疗的全面普及，大量医疗企业接入DS、华为等AI模型，开始摸索AI在医疗的应用。我们认为，1）拥有大量底层病人数据 的企业将有很大应用落地空间，2）拥有医保数据的企业有望深入应用AI，3）AI制药继续升级，建议关注此类公司。此外，积极关注1）创新药及其产业链 的技术革新与BD潜力；2）有业绩，基本面出现拐点的企业。 西南证券表示，2025年2月，国产大模型DeepSeek-R1全面开源与多领域适配，AI医疗迈入技术融合与行业重构的新阶段，DeepSeek的多模型协同能力成为 行业新范式。这种" ...

Policy Developments - Heilongjiang Province has initiated a joint action among eight departments to regulate illegal medical advertisements, particularly targeting "miracle doctor" ads that mislead consumers by using false credentials or endorsements [2] Drug and Device Approvals - Merck announced the launch of its new antibiotic, Recarbrio® (Imipenem/Cilastatin/Relebactam), in China, which is indicated for treating infections caused by sensitive Gram-negative bacteria in patients aged 18 and older [4] Capital Markets - Jingtai Holdings plans to acquire 90% of Shanghai Siwei Medical Technology for a total consideration of 250 million yuan, enhancing its capabilities in AI healthcare and drug development [6] - Yihe Jiaye has signed a strategic cooperation framework agreement with Shenzhen Hanyu Pharmaceutical and Shenzhen Hanyu Health Technology to develop a sleep health ecosystem through resource integration [7] Industry Developments - Kintor Pharmaceutical released preliminary clinical data for its CT0596 CAR-T cell injection targeting BCMA, currently under exploration for treating relapsed/refractory multiple myeloma [9] - Hanyu Pharmaceutical has agreed to collaborate with Shenzhen Carbon Cloud Peptide Technology on the development of a novel peptide drug targeting GLP-1R/GIPR/GCGR, which currently has no similar products approved for market [10] - Eli Lilly's tirzepatide has shown superior weight loss efficacy compared to Novo Nordisk's semaglutide in a head-to-head clinical trial, potentially reshaping the obesity treatment market [11]

Investment Rating - The report does not explicitly state an investment rating for the medical device industry. Core Insights - The Chinese medical device industry is experiencing rapid growth driven by policy reforms and increasing domestic demand, with a significant rise in the number of production enterprises from 16,356 in 2018 to 36,675 in 2023, reflecting a compound annual growth rate (CAGR) of 17.5% [5][13]. - The market for high-value medical devices (Class III) is expanding, with a notable increase in manufacturers, which grew by 15.5% from 2022 to 2023 [13]. - The medical device market in China is projected to grow from CNY 528.4 billion in 2018 to CNY 1,502.4 billion by 2028, with a CAGR of 14.9% [31]. Summary by Sections Chapter 1: Overview of the Chinese Medical Device Industry - The classification and layout of the medical device industry in China highlight the importance of production capacity and the number of devices held by medical institutions as key indicators of healthcare quality [4][6]. - Recent policy changes have lowered entry barriers for domestic manufacturers and improved the feasibility of remote consultations, enhancing service quality and efficiency [6][9]. Chapter 2: Current Development of the Chinese Medical Device Industry - The industry has undergone a period of contraction followed by recovery and stabilization, with significant regulatory changes promoting innovation and improving the quality and safety of domestic products [16][18]. - The number of registered medical devices has increased, with a shift towards innovative products, particularly in high-value categories [20][24]. Chapter 3: Analysis of the Overseas Expansion of Chinese Medical Devices - The export value of Chinese medical devices surged from CNY 162.2 billion in 2018 to CNY 807.6 billion in 2020, reflecting a CAGR of 123.1% [37]. - In 2023, the export of medical consumables surpassed diagnostic equipment, accounting for 44.9% of total exports, driven by competitive pricing and innovation [37][38]. Chapter 4: Frontier Development Trends in the Chinese Medical Device Industry - The integration of AI in medical devices is gaining momentum, with the Chinese government supporting digital healthcare initiatives to enhance local capabilities and reduce the gap with international standards [46][49]. - The report indicates a growing trend in the adoption of AI technologies in imaging devices, with a significant portion of approvals for AI medical devices in the imaging sector [51].

（原标题：一则消息引发恒生创新药ETF、港股通创新药ETF下跌，多家机构看好创新药板块） 一则消息，港股、A股、日本创新药板块突发大跌。 截至今日收盘，恒生创新药ETF、港股通创新药ETF、港股创新药50ETF、恒生医疗ETF、港股创新药 ETF基金跌超4%。 消息面上，特朗普又有新动作，他将于周一签署一项行政命令，让美国的处方药和药品价格将立即降低 30%至80%。 兴业证券继续看好创新+自主可控，并建议重点关注具备较好成长性和产业逻辑的细分领域。创新+国 际化仍是核心关键词，重点关注创新药，以及基本面开始改善的创新药产业链。同时，随着deepseek等 技术发展，我们认为AI医疗有望成为2025年医药板块的重要方向之一。此外，医疗器械2025年亦有望 迎来改善；2025年若经济基本面预期转好，消费医疗领域（中药OTC、医疗服务与连锁药店等）也有望 实现回升。 开源证券指出，疫情高基数、医疗合规化、产业内部调结构等多因素搅动下，近两年医药板块整体经营 有所波动：2025年第一季度，医药板块整体收入增速-6.13%，归母净利润增速-9.68%。产业调整已接近 尾声，医药指数已先行企稳回升：受行业整体经营承压， ...

Core Insights - The article highlights the significant potential of AI in the healthcare sector, particularly in remote medical services and diagnostics, with a focus on the acquisition of Shanghai Siwei Medical Technology Co., Ltd. by Jingtai Holdings for 250 million yuan [1][2][3] Company Summary - Jingtai Holdings has acquired 90% of Shanghai Siwei Medical, the largest remote ECG diagnostic service provider in China, to enhance its AI healthcare business and support drug development [1][2] - The acquisition will enable Jingtai to integrate clinical, molecular, and imaging data to develop precise and efficient remote diagnostic tools for cardiovascular diseases [2][6] - Jingtai aims to leverage Siwei's extensive structured ECG data and clinical experience to create a high-efficiency remote medical and AI-assisted diagnostic platform [6][7] Industry Summary - Cardiovascular diseases are the leading cause of death in China, accounting for over 45% of total deaths, with a significant market for ECG monitoring, estimated at 21 billion yuan [3][4] - The remote ECG testing market is projected to reach 10 billion yuan by 2022, driven by the increasing demand for advanced healthcare solutions amid a shortage of specialized medical professionals [3][4] - Government policies, such as the "Healthy China 2030" initiative, are promoting the integration of AI in healthcare, encouraging the development of remote medical services [4][5]

Group 1 - The pharmaceutical sector has recently experienced a rebound, with over 100 medical-themed funds achieving a return rate exceeding 10% year-to-date as of May 9, with some funds exceeding 40% [1][2] - Despite the overall positive performance of many medical-themed funds, there is significant performance divergence, with the worst-performing fund down over 13%, creating a gap of more than 50 percentage points between the best and worst performers [1][2] - Some investors are opting to sell their holdings despite the market recovery, driven by a "break-even" mentality after previous losses, leading to a noticeable shrinkage in fund sizes [1][3] Group 2 - Innovative drugs have emerged as the standout segment within the pharmaceutical market, with funds heavily invested in this area seeing substantial gains, such as the Zhongyin Hong Kong Stock Connect Medical Fund, which reported a return rate exceeding 38% [2] - Fund managers are adjusting their portfolios, reducing exposure to previously high-performing innovative drug stocks while increasing allocations to AI-related medical stocks, indicating a shift in investment strategy [2][3] - The overall investment logic in the pharmaceutical sector appears to be changing, with a growing recognition of China's innovative drug industry gaining a leading position globally, supported by favorable government policies [3][4] Group 3 - Despite the strong performance of the pharmaceutical market, some funds are still facing the risk of liquidation, with several funds showing a decline in size even after positive returns [3] - The industry has seen a significant increase in the number of new medical-themed funds being launched by various public fund institutions, indicating a growing interest in this sector [3] - The pharmaceutical industry is characterized by high uncertainty and policy risks, necessitating a cautious approach to investment, including diversification to mitigate potential risks [4]

2025.05. 11 本文字数：2500，阅读时长大约4分钟 作者 | 第一财经 曹璐 美国"对等关税"政策发酵，全球贸易格局继续调整，成为资本市场近期关注的焦点。Wind数据显 示，截至5月9日，近一个月来机构调研热度飙升，2210家上市公司迎来3068次调研，以区间18个交 易日计算，平均每天有超过170次调研。 这轮调研热潮中，电子、机械设备、医药生物等三大板块成为机构重点关注的领域。立讯精密 （002475.SZ）、水晶光电（002273.SZ）等公司吸引超300家机构扎堆调研。此外，机构投资者在关 注企业财报业绩的同时，也重点聚焦了关税冲击下的海外布局、成本转嫁策略等关键问题。 "财报季后和增量政策空窗期，仍建议关注具有产业进展的科技方向。"金鹰基金权益研究部金达莱对 第一财经表示，AI应用、人形机器人、智能驾驶等新质生产力方向近期已有所反弹，随着财报落 地，AI大模型产业进展或带动其再度有所表现，日历效应下利于节后资金回流和科技成长风格的估 值修复。 近一个月3068次调研 针对关税影响问题，该公司在调研中表示，目前市场上更多的是情绪上的恐慌，但从企业实际经营的 角度来看，大多数出口美国的终端产 ...

美国"对等关税"政策发酵，全球贸易格局继续调整，成为资本市场近期关注的焦点。Wind数据显示， 截至5月9日，近一个月来机构调研热度飙升，2210家上市公司迎来3068次调研，以区间18个交易日计 算，平均每天有超过170次调研。 这轮调研热潮中，电子、机械设备、医药生物等三大板块成为机构重点关注的领域。立讯精密 （002475.SZ）、水晶光电（002273.SZ）等公司吸引超300家机构扎堆调研。此外，机构投资者在关注 企业财报业绩的同时，也重点聚焦了关税冲击下的海外布局、成本转嫁策略等关键问题。 "财报季后和增量政策空窗期，仍建议关注具有产业进展的科技方向。"金鹰基金权益研究部金达莱对第 一财经表示，AI应用、人形机器人、智能驾驶等新质生产力方向近期已有所反弹，随着财报落地，AI 大模型产业进展或带动其再度有所表现，日历效应下利于节后资金回流和科技成长风格的估值修复。 近一个月3068次调研 Wind数据显示，截至5月9日，近一个月有2210家上市公司接待了来自机构投资者的3068次调研，合计 接待来访机构家数达5.28万家。申万一级行业中，电子、机械设备、医药生物三大板块成为机构重点关 注领域，相关调 ...